These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 33522271)
1. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection. Ren W; Xourafas D; Ashley SW; Clancy TE Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271 [TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
3. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715 [TBL] [Abstract][Full Text] [Related]
4. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392 [TBL] [Abstract][Full Text] [Related]
5. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. Ren W; Xourafas D; Ashley SW; Clancy TE J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122 [TBL] [Abstract][Full Text] [Related]
6. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344 [TBL] [Abstract][Full Text] [Related]
7. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Klaiber U; Schnaidt ES; Hinz U; Gaida MM; Heger U; Hank T; Strobel O; Neoptolemos JP; Mihaljevic AL; Büchler MW; Hackert T Ann Surg; 2021 Jan; 273(1):154-162. PubMed ID: 30921051 [TBL] [Abstract][Full Text] [Related]
9. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. Ren W; Xourafas D; Ashley SW; Clancy TE Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651 [TBL] [Abstract][Full Text] [Related]
10. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry. Schuhbaur J; Surovtsova I; Seufferlein T; Kokh D; Szotyori-Artz G; Winzler C; Schütz J; Uhl W; Tannapfel A; Morakis P BMC Cancer; 2024 Oct; 24(1):1280. PubMed ID: 39407151 [TBL] [Abstract][Full Text] [Related]
12. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery. Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994 [TBL] [Abstract][Full Text] [Related]
13. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Konishi T; Takano S; Takayashiki T; Suzuki D; Sakai N; Hosokawa I; Mishima T; Nishino H; Suzuki K; Nakada S; Ohtsuka M Ann Surg Oncol; 2024 Oct; 31(10):6992-7000. PubMed ID: 38926210 [TBL] [Abstract][Full Text] [Related]
14. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389 [TBL] [Abstract][Full Text] [Related]
15. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis. Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan. Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421 [TBL] [Abstract][Full Text] [Related]
17. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157 [TBL] [Abstract][Full Text] [Related]
18. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317 [TBL] [Abstract][Full Text] [Related]
19. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Terlizzi M; Buscail E; Boussari O; Adgié S; Leduc N; Terrebonne E; Smith D; Blanc JF; Lapuyade B; Laurent C; Chiche L; Belleannée G; Le Malicot K; Trouette R; Pouypoudat C; Vendrely V Acta Oncol; 2021 Sep; 60(9):1114-1121. PubMed ID: 34197269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]